ClinicalTrials.gg
RecruitingNCT07226427Updated Jul 6, 2026

A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

A Phase 1 interventional study of MEN2501 in Platinum-resistant Ovarian Cancer, sponsored by Stemline Therapeutics, Inc.. Recruiting at 15 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Stemline Therapeutics, Inc. (part of Menarini Group) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,780 studies in Ovarian Neoplasms with a site in United States — 277 open to participants now, 453 under way, 46 of them phase 3. Ovarian Neoplasms · United States.

Planned enrollment
442nd of 1,499
100 · median 47
Started
2026
with 65 others
Phase 1
548 of 1,780
74 open now
Primary completion
2027-12
later than 267 of 451 live
Registered
1,722nd of 1,780
by date

Among the 1,780 studies in Ovarian Neoplasms with a site in United States, this one is the 442nd largest by planned enrollment of the 1,499 interventional ones that give a count, is one of 66 that started in 2026, is one of 548 in phase 1, reaches primary completion later than 267 of the 451 other live ones, and was the 1,722nd registered.

Ovarian Neoplasms

3,389 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

277 of the 1,780 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:

272 more — sign in →

All 277 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,780 studies in Ovarian Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.

03

Conditions studied

  • Platinum-resistant Ovarian Cancer

Browse trials for

Keywords

  • MEN2501
  • First-in-Human
  • Ovarian Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants must have a histopathologically confirmed diagnosis of high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

Key Exclusion Criteria:

  • Participants with primary platinum- disease.

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Part A: MEN2501 Dose Escalation

    Drug: MEN2501

  • Experimental
    Part B: MEN2501 Dose Expansion & Optimization

    Drug: MEN2501

Interventions

  • DrugMEN2501

    Oral tablet

06

What researchers measure

Primary outcomes

  1. Part A Only: Number of Participants with Dose-limiting Toxicities (DLTs)

    Time frame: Cycle 1 (28 days/cycle)

  2. Part B Only: Recommended Phase 2 Dose (RP2D) of MEN2501

    Time frame: Up to approximately 6 months

Secondary outcomes

  1. Number of Participants with Treatment-emergent Adverse Events

    Time frame: Up to approximately 7 months

  2. Overall Response Rate

    Time frame: Up to approximately 7 months

  3. Duration of Objective Response

    Time frame: Up to approximately 7 months

  4. Clinical Benefit Rate

    Time frame: Up to approximately 7 months

  5. Progression-free Survival

    Time frame: Up to approximately 12 months

  6. Overall Survival

    Time frame: Up to approximately 12 months

  7. Time To Response

    Time frame: Up to approximately 7 months

  8. Area Under the Plasma Concentration-time Curve (AUC) of MEN2501

    Time frame: Up to approximately 6 months

07

Study locations

15 of 15 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 22 months after the start.

Of 210 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 22 months is below that.

Counting every sponsor, half of 380 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2025
First posted
Nov 10, 2025
StartActual
Jan 10, 2026
Primary completionEst.
Dec 2, 2027
CompletionEst.
Jun 2, 2028
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07226427
Responsible party
Sponsor
First posted
Nov 10, 2025
Start date
Jan 10, 2026
Primary completion
Dec 2, 2027 (estimated)
Completion
Jun 2, 2028 (estimated)
Last update
Jul 6, 2026

Study contacts

Medical Director
study director · Stemline Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion